NASDAQ:GRFS

Grifols Competitors

$17.90
-0.07 (-0.39 %)
(As of 05/5/2021 04:30 PM ET)
Add
Compare
Today's Range
$17.75
$18.29
50-Day Range
$16.00
$18.60
52-Week Range
$14.81
$20.98
Volume507,730 shs
Average Volume881,454 shs
Market Capitalization$12.31 billion
P/E Ratio15.98
Dividend Yield0.78%
Beta0.59

Competitors

Grifols (NASDAQ:GRFS) Vs. ALXN, BGNE, RPRX, GMAB, CVAC, and HZNP

Should you be buying GRFS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Grifols, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), CureVac (CVAC), and Horizon Therapeutics Public (HZNP).

Alexion Pharmaceuticals (NASDAQ:ALXN) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Alexion Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Grifols12.79%10.65%4.79%

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Grifols' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.52$2.40 billion$9.7417.44
Grifols$5.71 billion2.15$700.16 million$1.1715.30

Alexion Pharmaceuticals has higher earnings, but lower revenue than Grifols. Grifols is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Alexion Pharmaceuticals and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals015512.33
Grifols03502.63

Alexion Pharmaceuticals presently has a consensus target price of $158.0476, suggesting a potential downside of 6.97%. Given Alexion Pharmaceuticals' higher probable upside, research analysts clearly believe Alexion Pharmaceuticals is more favorable than Grifols.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Grifols on 12 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares BeiGene and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Grifols12.79%10.65%4.79%

Earnings & Valuation

This table compares BeiGene and Grifols' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million65.40$-948,630,000.00($15.80)-19.33
Grifols$5.71 billion2.15$700.16 million$1.1715.30

Grifols has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for BeiGene and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
Grifols03502.63

BeiGene presently has a consensus target price of $319.3750, suggesting a potential upside of 4.62%. Given BeiGene's higher probable upside, research analysts clearly believe BeiGene is more favorable than Grifols.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Insider and Institutional Ownership

60.7% of BeiGene shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Grifols beats BeiGene on 8 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Grifols (NASDAQ:GRFS) are both large-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Royalty Pharma and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Grifols12.79%10.65%4.79%

Earnings & Valuation

This table compares Royalty Pharma and Grifols' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Grifols$5.71 billion2.15$700.16 million$1.1715.30

Grifols has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 0.8%. Grifols pays out 12.0% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Royalty Pharma and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Grifols03502.63

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 24.04%. Given Royalty Pharma's higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Grifols.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S (NASDAQ:GMAB) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Genmab A/S and Grifols' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million29.90$324.68 million$0.5171.92
Grifols$5.71 billion2.15$700.16 million$1.1715.30

Grifols has higher revenue and earnings than Genmab A/S. Grifols is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Grifols12.79%10.65%4.79%

Analyst Recommendations

This is a summary of current recommendations and price targets for Genmab A/S and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24902.47
Grifols03502.63

Genmab A/S presently has a consensus target price of $41.5714, suggesting a potential upside of 13.21%. Given Genmab A/S's higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Grifols.

Volatility and Risk

Genmab A/S has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Summary

Genmab A/S beats Grifols on 8 of the 13 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Grifols and CureVac's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$5.71 billion2.15$700.16 million$1.1715.30
CureVacN/AN/AN/AN/AN/A

Grifols has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Grifols and CureVac's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Grifols12.79%10.65%4.79%
CureVacN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Grifols and CureVac, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Grifols03502.63
CureVac11302.40

CureVac has a consensus target price of $58.3333, suggesting a potential downside of 42.20%. Given CureVac's higher possible upside, analysts clearly believe CureVac is more favorable than Grifols.

Summary

Grifols beats CureVac on 7 of the 8 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and Horizon Therapeutics Public (NASDAQ:HZNP) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Grifols and Horizon Therapeutics Public's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$5.71 billion2.15$700.16 million$1.1715.30
Horizon Therapeutics Public$1.30 billion15.39$573.02 million$1.9446.03

Grifols has higher revenue and earnings than Horizon Therapeutics Public. Grifols is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Grifols and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Grifols12.79%10.65%4.79%
Horizon Therapeutics Public43.55%25.66%14.19%

Analyst Ratings

This is a summary of recent ratings and price targets for Grifols and Horizon Therapeutics Public, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Grifols03502.63
Horizon Therapeutics Public001103.00

Horizon Therapeutics Public has a consensus target price of $111.3636, suggesting a potential upside of 24.50%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Grifols.

Risk and Volatility

Grifols has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Grifols on 12 of the 14 factors compared between the two stocks.


Grifols Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$169.91-0.8%$37.22 billion$4.99 billion39.70Earnings Announcement
Analyst Report
BeiGene logo
BGNE
BeiGene
1.1$305.40-1.6%$28.45 billion$428.21 million-15.11Upcoming Earnings
Insider Selling
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.81-1.6%$25.78 billionN/A0.00Upcoming Earnings
Genmab A/S logo
GMAB
Genmab A/S
1.4$36.68-3.0%$23.34 billion$804.57 million28.43
CureVac logo
CVAC
CureVac
0.7$101.20-7.8%$20.40 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$89.30-1.6%$20.01 billion$1.30 billion24.40Earnings Announcement
Insider Selling
News Coverage
Gap Up
Catalent logo
CTLT
Catalent
1.7$106.48-2.8%$17.62 billion$3.09 billion67.82Earnings Announcement
Analyst Downgrade
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$132.67-0.8%$15.47 billion$219.75 million-16.94Earnings Announcement
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$31.11-0.6%$14.80 billion$3.07 billion-54.58Upcoming Earnings
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.68-0.9%$14.25 billion$1.70 billion17.78Earnings Announcement
Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$151.46-3.0%$13.91 billion$12.98 million-49.99Upcoming Earnings
Insider Selling
Gap Up
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$70.25-1.7%$11.48 billion$2.32 billion58.06
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.36-2.6%$11.02 billion$16.89 billion-2.82Earnings Announcement
Analyst Downgrade
Analyst Revision
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.03-0.3%$9.94 billion$8.60 billion-5.14Earnings Announcement
Analyst Report
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$37.36-2.8%$9.35 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$170.82-6.2%$9.11 billion$2.16 billion53.89Earnings Announcement
News Coverage
Gap Up
United Therapeutics logo
UTHR
United Therapeutics
1.5$198.14-1.4%$8.88 billion$1.45 billion18.75News Coverage
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$52.94-2.0%$8.04 billion$40.56 million-15.52Upcoming Earnings
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$151.51-2.5%$7.98 billion$3.34 million-19.68Upcoming Earnings
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$138.18-0.2%$7.44 billion$14.98 million-16.83News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.47-0.0%$6.90 billion$87.99 million-79.13Earnings Announcement
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$106.01-3.9%$6.87 billion$103.71 million-24.15Earnings Announcement
Analyst Upgrade
Insider Selling
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.96-0.1%$6.86 billion$311.33 million-127.30Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$39.89-5.2%$5.92 billion$1.12 billion83.10Earnings Announcement
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.77-1.7%$5.80 billion$380.83 million-9.31Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.48-1.2%$5.76 billion$150,000.00-19.57Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.3$42.02-0.3%$5.63 billion$4.84 billion-700.22Upcoming Earnings
Allakos logo
ALLK
Allakos
1.7$101.12-3.1%$5.58 billionN/A-36.90Upcoming Earnings
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$90.95-0.1%$5.31 billion$66.51 million16.78Earnings Announcement
Analyst Revision
Galapagos logo
GLPG
Galapagos
1.3$76.90-0.4%$5.06 billion$1.00 billion-11.65Upcoming Earnings
Schrödinger logo
SDGR
Schrödinger
1.4$68.82-2.0%$4.92 billion$85.54 million0.00Upcoming Earnings
Analyst Downgrade
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$71.94-1.2%$4.41 billionN/A-5.86Upcoming Earnings
Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$58.85-1.4%$4.18 billion$4.31 million-2.04
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$70.80-0.5%$4.16 billion$6.87 million-6.84Earnings Announcement
Analyst Report
News Coverage
LEGN
Legend Biotech
1.3$30.42-0.2%$4.04 billion$64.39 million0.00
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$48.19-3.1%$4.00 billionN/A-6.49Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.59-2.2%$3.96 billion$204.89 million-33.24
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.30-0.5%$3.88 billion$806.43 million-9.11Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$53.27-0.5%$3.75 billion$117.91 million-10.81Earnings Announcement
Alkermes logo
ALKS
Alkermes
1.2$22.05-1.1%$3.58 billion$1.17 billion-47.93Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.57-2.4%$3.55 billionN/A-20.11Analyst Downgrade
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.6%$3.43 billion$114.62 million-7.53Upcoming Earnings
Arvinas logo
ARVN
Arvinas
1.7$67.16-1.3%$3.33 billion$42.98 million-26.23Earnings Announcement
Unusual Options Activity
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.00-1.1%$3.33 billion$26.52 million-8.02Upcoming Earnings
Analyst Report
Insmed logo
INSM
Insmed
1.2$30.52-2.6%$3.23 billion$136.47 million-11.74Upcoming Earnings
Analyst Downgrade
Gap Up
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.55-0.0%$3.17 billionN/A-53.51Upcoming Earnings
Analyst Report
Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$61.01-3.1%$3.17 billion$1.11 billion19.62Earnings Announcement
Analyst Report
Unusual Options Activity
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$19.40-0.6%$3.10 billion$339.08 million-11.28Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$21.53-2.4%$2.90 billion$80.43 million102.53Increase in Short Interest
News Coverage
Gap Down
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.18-1.1%$2.85 billion$644.77 million-10.72News Coverage
This page was last updated on 5/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.